Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

CXCR4 (Chemokine (C-X-C motif) receptor 4)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

SureSeq CLL + CNV V3 NGS Panel

SureSeq™ CLL + CNV Panel

SureSeq™ Pan-Myeloid Panel

SureSeq CLL + CNV V3 NGS Panel

SureSeq™ CLL + CNV Panel

SureSeq™ Pan-Myeloid Panel

›

CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B
CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C2 – Inclusion Criteria rituximab + ixazomib Sensitive : C2	rituximab + ixazomib Sensitive: C2 – Inclusion Criteria rituximab + ixazomib Sensitive : C2
CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2
CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	ibrutinib + BMS-936564 Sensitive: C2 – Inclusion Criteria ibrutinib + BMS-936564 Sensitive : C2	ibrutinib + BMS-936564 Sensitive: C2 – Inclusion Criteria ibrutinib + BMS-936564 Sensitive : C2
CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3
CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	rituximab Sensitive: C3 – Early Trials rituximab Sensitive : C3	rituximab Sensitive: C3 – Early Trials rituximab Sensitive : C3
CXCR4 G336X	Waldenstrom Macroglobulinemia	CXCR4 G336X	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3
CXCR4 S338X	Waldenstrom Macroglobulinemia	CXCR4 S338X	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3
CXCR4 H350fs*	Waldenstrom Macroglobulinemia	CXCR4 H350fs*	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3
CXCR4 S338X + TP53 R196X	Waldenstrom Macroglobulinemia	CXCR4 S338X + TP53 R196X	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3
CXCR4 K327fs*	Waldenstrom Macroglobulinemia	CXCR4 K327fs*	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3